



1651 JFW

Docket No.: 102 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wang
Serial No.: 10/655,861 Examiner: Unassigned
Filed: September 5, 2003 Group: 1651
For: Method of Treatment of Asthma Using Antibodies to Complement Component C5

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

Date of Deposit: June 24, 2004

I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Information Disclosure Statement
- ☒ PTO 1449 with Cited References
- ☒ Return Postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.


Rebecca Layman

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410



Docket: 102 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Wang

Serial No: 10/655,861

Examiner: Unassigned

Filed: September 5, 2003

Group Art Unit: 1651

For: **Method of Treatment of Asthma Using Antibodies to Complement Component C5**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 C.F.R. §1.56, Applicants submit the enclosed reference for the Examiner's consideration.

It is respectfully requested that the reference(s) submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the reference(s) is/are enclosed. This submission is believed to be in compliance with 37 C.F.R. §1.97 and 37 C.F.R. §1.98.

The citation of the listed item(s) is not a representation that it constitutes a complete or exhaustive listing of prior art or that it constitutes prior art. The item(s) listed is/are submitted in good faith, but is/are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner, it will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

() This information disclosure statement is being filed within three (3) months of the filing date of this application.

() This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.

(x) To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.

() Enclosed is a certificate under 37 C.F.R. §1.97 (e)(i).

() Enclosed is a petition under 37 C.F.R. §1.97 (d)

(.) Please charge the petition fee of \$130.00 required under 37 C.F.R. §1.17 (i) (1) to Deposit Account No. 01-0483.

() As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under 37 C.F.R. §1.113 or the mailing of a notice of allowance under 37 C.F.R. §1.113, and is accompanied by the \$220.00 fee as provided for in 37 C.F.R. §1.17(p).

() Please charge the \$240.00 fee required by 37 C.F.R. §1.17(p) to Deposit Account No. 01-0483.

(x) Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. §1.16 and/or 37 C.F.R. §1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefor. **TWO COPIES OF THIS SHEET ARE ENCLOSED.**

Early and favorable consideration of the case is respectfully requested.

Dated: June 24, 2004

Mark Farber
Mark Farber
Registration No. 34,159
Attorney for Applicants

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410
(203) 271-8319



Form PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK	ATTY. DOCKET NO. 102 US	SERIAL NO. 10/655,861
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		
	APPLICANT Wang	
	FILING DATE September 5, 2003	GROUP Art Un: 1651

U.S. PATENT DOCUMENT

EXAMINER INITIALS	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS
	6 3 1 6 5 0 2	11/13/2001	Lai et al.		
	6 3 5 5 2 4 5	03/12/2002	Evans et al.		

FOREIGN PATENT DC

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	
					YES	NO
	0 6 4 9 4 6 8	EP				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pa

	Lukacs et al. Complement-dependent immune complex-induced bronchial inflammation and hyperreactivity. Am J Physiol Lung Cell Mol Physiol. 280:L512-L518, 2001.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with
if not in conformance and not considered. Include copy of this form with next communicati